PS3 (GLP-3 Triple Agonist)

PS3 is a proprietary synthetic metabolic peptide analog classified as a GLP-3 (R) triple-agonist — simultaneously engaging GLP-1, GIP, and glucagon receptors. Supplied as a lyophilized powder in 12 mg research vials, PS3 is studied in controlled laboratory environments for its role in metabolic signaling pathway modulation, receptor–ligand interaction modeling, and comparative evaluation of synthetic peptide conjugation strategies. Research investigations focus on adipose tissue regulation, insulin secretion dynamics, energy expenditure pathway analysis, and structural integrity under various storage and reconstitution conditions. Each batch is third-party HPLC-verified for purity ≥98%.